IL1β Promotes Atheroprotective Changes in Late Stage Atherosclerotic Lesions
IL1β 促进晚期动脉粥样硬化病变的动脉粥样硬化变化
基本信息
- 批准号:10005432
- 负责人:
- 金额:$ 3.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody TherapyApolipoprotein EArterial Fatty StreakAtherosclerosisCCL2 geneCardiovascular systemCause of DeathCell LineageCell ProliferationCellsCessation of lifeCharacteristicsClinical TrialsCoculture TechniquesCoronaryDataEndothelial CellsEventExhibitsGenesGoalsHumanIL1R1 geneImmunoglobulin GIn VitroIncidenceInflammationInflammatoryInterleukin 4 ReceptorInterleukin-1Interleukin-1 betaInterleukin-4LesionLesion by MorphologyLesion by StageMaintenanceMediatingMusMyocardial InfarctionNaturePathogenesisPatient-Focused OutcomesPatientsPhase III Clinical TrialsPhenotypePlayPostdoctoral FellowProductionProtein IsoformsProteinsRecurrenceResearchResearch ProposalsRoleRuptureSecondary toSignal TransductionSmooth Muscle MyocytesStrokeTestingTherapeuticThickTransgenesatheroprotectiveatherosclerotic plaque ruptureatherothrombosiscardiovascular risk factorcell typeconditional knockoutcytokinedesignfeedinghigh riskimprovedindexingmacrophagemonocytemouse modelneutralizing antibodypluripotencypre-clinicalpromoterrecruitstem cellsstroke therapyvascular smooth muscle cell proliferationwestern diet
项目摘要
PROJECT SUMMARY: Complications resulting from rupture of unstable atherosclerotic lesions, including myocardial
infarction and stroke, are the leading cause of death worldwide. Despite decades of research, the mechanisms and
factors leading to plaque rupture remain poorly understood. It is generally accepted that lesions with a high smooth
muscle cell (SMC) to macrophage (Mϕ) ratio are less likely to rupture. However in the setting of atherosclerosis, SMC
down-regulate their characteristic markers and express markers of other cells types and thus are undetectable using
traditional markers. Indeed, rigorous SMC lineage tracing studies by our lab using Myh11 ERT2Cre eYFP ApoE-/- mice
have shown that >80% of SMC within lesions lack expression of the markers previously used for their identification
and that nearly 30% of these cells have activated multiple markers of Mϕ. Therefore, the number of SMC within
lesions has not only been grossly underestimated, but many cells thought to be Mϕ are actually SMC-derived. Of even
greater significance, we showed that SMC-specific conditional knockout of the stem cell pluripotency genes Klf4 and
Oct4 had a profound impact on the pathogenesis of lesions including alterations in multiple indices of plaque stability.
However, contrary to the dogma that SMC are always atheroprotective, we showed they can be either
atheroprotective or -promoting depending on the nature of their phenotypic transitions. Taken together, studies
highlight the importance of identifying factors and mechanisms that promote beneficial changes in SMC phenotype.
An ongoing clinical trial is investigating neutralization of interleukin-1 in high-risk cardiovascular patients. The
overarching hypothesis is that inflammation drives atherosclerosis, and that inhibition of inflammation will improve
patient survival. However, there is a lack of preclinical evidence that neutralization of IL1 will confer beneficial effects
in the setting of advanced atherosclerosis. Indeed, recent studies from our lab, which included the applicant, showed
that treatment of our Myh11 ERT2Cre eYFP ApoE-/- mice with the Novartis IL1-neutralizing antibody after the
establishment of advanced atherosclerosis resulted in multiple changes consistent with reduced plaque stability
including marked reductions in the number of SMC-derived eYFP+ cells within the fibrous cap, and replacement of
these cells with Mϕ. Studies in this proposal will test the hypothesis that IL1 signaling in SMC is critical for
maintenance of plaque stability in late-stage atherosclerosis. Aim 1 test the hypothesis that the detrimental effects of
anti-IL1 Ab treatment on late-stage atherosclerosis are primarily mediated through IL1R1 signaling in SMC and that
this results in deleterious phenotypic transitions in lesion SMC. Aim 2 will test the hypothesis that increased production
of interleukin-4 (IL4) following anti-IL1 Ab treatment of Myh11 ERT2Cre eYFP ApoE-/- mice with advanced lesions
contributes to the deleterious effects of anti-IL1 Ab treatment on late-stage lesion pathogenesis observed in our initial
studies. These studies will greatly increase our understanding of IL1 signaling in late-stage atherosclerosis and may
identify approaches to augment current therapies to promote atheroprotective changes in SMC phenotypes and
ultimately improve patient outcomes.
项目摘要:不稳定的动脉粥样硬化性病变,包括心肌破裂引起的并发症
脑梗塞和中风是世界范围内的主要死亡原因。尽管进行了数十年的研究,但这些机制和
导致斑块破裂的因素仍然知之甚少。一般认为,皮损具有较高的光滑度
肌细胞(SMC)与巨噬细胞(Mϕ)的比例不太可能破裂。然而,在动脉粥样硬化的背景下,SMC
下调其特征标记和其他细胞类型的表达标记,因此无法使用
传统的记号笔。事实上,我们实验室使用MYH11 ERT2 Cre EYFP ApoE-/-小鼠进行的严格的SMC血统追踪研究
已经表明,病变内80%的SMC缺乏以前用于鉴定它们的标志物的表达
其中近30%的细胞激活了多个M-ϕ标志物。因此,SMC的数量在
损伤不仅被严重低估,而且许多被认为是Mϕ的细胞实际上是SMC来源的。偶数的
更有意义的是,我们发现SMC特异性的条件敲除干细胞多能性基因Klf4和
Oct4对病变的发病机制产生了深远的影响,包括斑块稳定性的多项指标的改变。
然而,与SMC总是具有动脉粥样硬化保护作用的教条相反,我们证明了它们可以是
抗动脉粥样硬化或促进动脉粥样硬化取决于其表型转变的性质。总而言之,研究
强调确定促进SMC表型有益变化的因素和机制的重要性。
一项正在进行的临床试验正在调查高危心血管患者中和白细胞介素1的情况。这个
最重要的假设是炎症导致动脉粥样硬化,而对炎症的抑制将会改善。
病人存活率。然而,缺乏临床前证据表明中和IL1会带来有益的效果。
在晚期动脉粥样硬化的背景下。事实上,我们实验室最近的研究表明,包括申请人在内的
诺华IL-1中和抗体治疗MYH11ERT2 Cre EYFP ApoE-/-小鼠
晚期动脉粥样硬化的建立导致与斑块稳定性降低一致的多种变化
包括显著减少纤维帽内SMC来源的EYFP+细胞的数量,并取代
这些具有Mϕ的细胞。这项建议中的研究将检验这一假设,即SMC中的IL1信号对
晚期动脉粥样硬化斑块稳定性的维持。目标1检验这样一个假设,即
抗白介素1抗体治疗晚期动脉粥样硬化主要通过血管内皮细胞中白介素1受体1信号转导而实现
这会导致病变的SMC发生有害的表型转变。目标2将检验增加产量的假设
抗IL-1单抗治疗晚期皮损MYH11ERT2 Cre EYFP ApoE-/-小鼠后IL-4的变化
在我们最初观察到的晚期病变发病机制中,抗IL-1抗体治疗的有害影响是有贡献的
学习。这些研究将大大增加我们对晚期动脉粥样硬化中IL1信号的理解,并可能
确定加强现有疗法以促进SMC表型和动脉粥样硬化保护改变的方法
最终改善患者的预后。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis.
- DOI:10.1161/circulationaha.120.046672
- 发表时间:2020-11-24
- 期刊:
- 影响因子:37.8
- 作者:Alencar GF;Owsiany KM;Karnewar S;Sukhavasi K;Mocci G;Nguyen AT;Williams CM;Shamsuzzaman S;Mokry M;Henderson CA;Haskins R;Baylis RA;Finn AV;McNamara CA;Zunder ER;Venkata V;Pasterkamp G;Björkegren J;Bekiranov S;Owens GK
- 通讯作者:Owens GK
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice.
- DOI:10.3791/59139
- 发表时间:2019-02
- 期刊:
- 影响因子:0
- 作者:Sidney Mahan;Mingjun Liu;Richard A. Baylis;Delphine Gomez
- 通讯作者:Sidney Mahan;Mingjun Liu;Richard A. Baylis;Delphine Gomez
Multiple cell types contribute to the atherosclerotic lesion fibrous cap by PDGFRβ and bioenergetic mechanisms.
- DOI:10.1038/s42255-020-00338-8
- 发表时间:2021-03
- 期刊:
- 影响因子:20.8
- 作者:Newman AAC;Serbulea V;Baylis RA;Shankman LS;Bradley X;Alencar GF;Owsiany K;Deaton RA;Karnewar S;Shamsuzzaman S;Salamon A;Reddy MS;Guo L;Finn A;Virmani R;Cherepanova OA;Owens GK
- 通讯作者:Owens GK
Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease.
- DOI:10.1161/circresaha.121.318322
- 发表时间:2021-06-11
- 期刊:
- 影响因子:20.1
- 作者:Baylis RA;Smith NL;Klarin D;Fukaya E
- 通讯作者:Fukaya E
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice.
- DOI:10.1038/s41591-018-0124-5
- 发表时间:2018-09
- 期刊:
- 影响因子:82.9
- 作者:Gomez D;Baylis RA;Durgin BG;Newman AAC;Alencar GF;Mahan S;St Hilaire C;Müller W;Waisman A;Francis SE;Pinteaux E;Randolph GJ;Gram H;Owens GK
- 通讯作者:Owens GK
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Baylis其他文献
Richard Baylis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Baylis', 18)}}的其他基金
IL1β Promotes Atheroprotective Changes in Late Stage Atherosclerotic Lesions
IL1β 促进晚期动脉粥样硬化病变的动脉粥样硬化变化
- 批准号:
9395309 - 财政年份:2017
- 资助金额:
$ 3.1万 - 项目类别:
IL1β Promotes Atheroprotective Changes in Late Stage Atherosclerotic Lesions
IL1β 促进晚期动脉粥样硬化病变的动脉粥样硬化变化
- 批准号:
9769122 - 财政年份:2017
- 资助金额:
$ 3.1万 - 项目类别:
相似海外基金
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 3.1万 - 项目类别:
Research Grant
Development of CD81 Antibody Therapy for Osteosarcoma - Focused on Exosomes -
骨肉瘤 CD81 抗体疗法的开发 - 专注于外泌体 -
- 批准号:
23K08593 - 财政年份:2023
- 资助金额:
$ 3.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 3.1万 - 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
- 批准号:
2246487 - 财政年份:2023
- 资助金额:
$ 3.1万 - 项目类别:
Standard Grant
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10511223 - 财政年份:2022
- 资助金额:
$ 3.1万 - 项目类别:
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10643886 - 财政年份:2022
- 资助金额:
$ 3.1万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10511323 - 财政年份:2022
- 资助金额:
$ 3.1万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10657706 - 财政年份:2022
- 资助金额:
$ 3.1万 - 项目类别:
Hacking Co-Stimulatory Receptors with Targeted Checkpoint Antibody Therapy
用靶向检查点抗体疗法攻击共刺激受体
- 批准号:
574961-2022 - 财政年份:2022
- 资助金额:
$ 3.1万 - 项目类别:
University Undergraduate Student Research Awards
Imaging the multifaceted response to a bispecific antibody therapy
双特异性抗体疗法的多方面反应成像
- 批准号:
10451574 - 财政年份:2021
- 资助金额:
$ 3.1万 - 项目类别: